Jodie Morrison, Q32 Bio CEO

November 16, 2023 08:44 AM ESTUpdated 03:01 PM

Q32 Bio to take Homology Medicines’ Nasdaq spot to fund PhII trials in autoimmune, inflammatory conditions

Kyle LaHucik

Biotech Correspondent

The reverse mergers are flowing. Q32 Bio will take Homology Medicines’ place on the Nasdaq, the companies said Thursday …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

AstraZeneca details its oral SERD 'switching' regimen as feasibility questions remain

Takeda, Protagonist unveil plenary data for potential blockbuster rare blood disease drug

As life-saving checkpoint drugs move to earlier cancers, researchers debate how best to use them

Arvinas, Pfizer's PROTAC in breast cancer no better than oral SERDs

Gilead, Merck reveal 'practice-changing' data for Trodelvy-Keytruda combo in aggressive breast cancer

sponsored

From weeks to days: how Aizon Intelligent Agents transform pharma validation